Navigation Links
NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan

SOPHIA ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today provided an update on the phase 2a study for NCX 1000, which is covered by its codevelopment agreement with Axcan Pharma Inc. A preliminary analysis of 11 patients from this proof-of-concept study in portal hypertension confirmed the safety profile of NCX 1000 but did not demonstrate the efficacy required to support the continuation of this clinical trial. As a consequence, Axcan and NicOx have agreed not to further pursue the development of NCX 1000 and to terminate the trial.

The trial was a phase 2a, double-blind, dose-escalating proof-of-concept study in which 11 patients with portal hypertension were enrolled in a single clinical center in Spain. Portal hypertension is abnormally raised blood pressure in the portal vein, which carries blood from the digestive system to the liver (see NOTE). Patients were randomized to receive either placebo or escalating doses of NCX 1000 (500mg, 1000mg and 2000mg as the first three doses during the first two days). This was followed by 2000mg (or the maximum tolerated dose) three times a day for the following 14 days.

The primary endpoint of the trial was defined as the comparison between patients' portal pressure in the fasting state on day 16 of treatment with the corresponding baseline values. A secondary endpoint was the same comparison following the consumption of a controlled meal and additional endpoints were based on the response rate (defined in terms of portal pressure reduction), the increase in liver blood flow, clinical safety, tolerability and pharmacokinet ics.

NCX 1000 showed good safety and tolerability, confirming the results observed in two previous phase 1 studies, and NicOx and Axcan will now proceed with further data analysis and full results will be disclosed at a later date.

Maarten Beekman, Vice President of Clinical Devel
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NicOx Provides Update the Phase Study for NCX Conducted With Axcan
(Date:11/25/2009)...5/PRNewswire-USNewswire/--RemediumTechnologiesInc....severebleeding,wonfirstprizeand$10,000intheMostPro...enge2009,companyofficialsannouncetoday. ,, Sele...ium,steampitchedtheirinventionattheGSCSecuritySumm... Remedium( www.remediumtechnologies.com )isdevelop...
(Date:11/25/2009)...RNewswire-Asia-FirstCall/--ChinaSkyOne,Medical,Inc... ),a,leadingfullyintegratedpharmaceuticalcompanyde...ple,sRepublicofChina("PRC"),today,announcedthatthe...r,theControlofPharmaceuticalandBiologicalProducts(...nosticKitforHumanProstateSpecific,Antigen(Colloida...
(Date:11/25/2009)...25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX...rebloodanalysissystems,announcedtodaythatClintSeve...tthe21stAnnualPiperJaffrayHealthCareConferenceonWe...llbeheldattheNewYorkPalaceHotelinNewYorkCity. ,...ndmarketsportablebloodanalysissystemsforuseinanyve...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3FDA Alert 3A New USP Standards for Heparin Products Will Result in Decreased Potency 5149 1FDA Alert 3A New USP Standards for Heparin Products Will Result in Decreased Potency 5149 2FDA Alert 3A New USP Standards for Heparin Products Will Result in Decreased Potency 5149 3Scripps research scientists find missing puzzle piece of powerful DNA repair complex 58672 1Scripps research scientists find missing puzzle piece of powerful DNA repair complex 58672 2Scripps research scientists find missing puzzle piece of powerful DNA repair complex 58672 3Scripps research scientists find missing puzzle piece of powerful DNA repair complex 58672 4Human Proteome Organization honors PNNL scientist 58670 1
... 2007 APA Meeting -, COLLEGEVILLE, Pa., May 21, 20...udies examining safety and efficacy of,desvenlafax...,inhibitor (SNRI) being studied as a potential tre...MDD), were presented today at the,2007 American Ps...,Calif., by Wyeth Pharmaceuticals, a division of W...
...ong-term Response at Stable Doses, According to,Ne...ATLANTA, May 22, 2007 /PRNewswire/ -- UCB announce...se Week 2007 (DDW),demonstrated long-term response... with Cimzia (certolizumab pegol), the only Fc-fre...called PRECiSE 3 (P3), is a long-term open label,c...
Other Medicine Technology:New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8UCB Presents Long-Term CImzia Data in Crohn's Disease 2UCB Presents Long-Term CImzia Data in Crohn's Disease 3UCB Presents Long-Term CImzia Data in Crohn's Disease 4UCB Presents Long-Term CImzia Data in Crohn's Disease 5
(Date:11/27/2009)... new interactive anatomy education apps from Modal...ealth sciences learning opportunities for iPhone a...C (Vocus) November 27, 2009 -- Modality, Inc. an...ion of Wolters Kluwer Health, today announced the ...n the App Store. Clemente’s Anatomy, Rohen&r...
(Date:11/26/2009)...tetrathiomolybdate (TM) has been shown in studies ..., a disease caused by an overload of copper, and c...y little, however, is known about how the drug wor...Northwestern University researchers now has provid...ture of TM bound to copper-loaded metallochaperone...
(Date:11/26/2009)...avid Kim of the Live Life Again Center, a practice...of a growing number of physicians who are taking ...nnect with individuals who are interested in surgi... Dr. Kim is utilizing Facebook to share before-and...ith the community. , Dall...
(Date:11/25/2009)...wswire-USNewswire/--WhenmostpeopleheartheacronymTM...ivepatientsthehelptheyneed.TMJstandsfortheTemporal...acts/connectswithyourskull(temporalbone). ,, Th...painwithchewing,clickingorpoppingofthejaw.Butmanyo...:headaches,fatigue,sleepdisturbances,irritability,...
(Date:11/25/2009)...re/-SentinelleMedicalInc.,aleadingmanufacturerofbr...esasuiteofnewleadingedgeclinicalapplicationsonitsA...RadiologicalSocietyofNorthAmerica(RSNA)annualmeeti...applicationsleveragetheuniquehighqualityimagesgene...pportmultipleimagingmodalitiesformulti-parametrica...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3
...o bear the brunt of police inquiries as focus shif...ravel the hands behind the foiled terror attacks i... also quizzed five doctors of foreign origin, four...ng that has been presented to us by the police tha...
...'s showpiece economic cities has urged his 11 mill... worsening traffic and pollution woes, state media...ty of Shenzhen, just across from the border from H...top buying cars," Xu Zongheng, the city's mayor wa...
...enient Truth" to heated Congressional debates abou..., the issue of coal's place in supplying America's...nce in recent months. A research institute...al discussions of the process. At the U...
...weeks pregnant with rocker boyfriend Joel Madden's...e Life" star, is reported to have shared the joyfu..., including Mischa Barton. However, she is neithe...den might be thinking about tying the nuptial knot...
... a way to produce blood vessels by engineering tis...esearchers at the University at Buffalo Department...e bone marrow is an excellent source of adult stem...ions. According to Dr. Stelios T. Andreadi...
...ity of Nottingham are amassing an arsenal of weapo...the most deadly of hospital superbugs . It in...ences are so strong it can resist most antibiotics...ociated Infections (CHAI), with Dr Peter Mullany a...
Other Medicine News:Health News:More Indian Doctors Questioned in Australia as UK Terror Plot Inquiry Widens 2Health News:An Inconvenient Truth-Coal to Liquid 2Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2Health News:The Hospital Superbugs 2Health News:The Hospital Superbugs 3
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products: